The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization.
David T HuangErin K McCrearyJ Ryan BariolaRichard J WadasKevin E KipOscar C MarroquinStephen KoscumbKevin CollinsJudith A ShovelMark SchmidhoferMary Kay WisniewskiColleen SullivanDonald M YealyMeredith AxeDavid A NaceGhady HaidarTina KhademKelsey LinstrumGraham M SnyderChristopher W SeymourStephanie K MontgomeryBryan J McVerryLindsay BerryScott BerryRussell MeyersAlexandra WeissmanOctavia M Peck-PalmerAlan WellsRobert BartDebbie L AlbinTami MinnierDerek C AngusPublished in: Trials (2021)
ClinicalTrials.gov Identifier: NCT04790786 . Registered March 10, 2021 FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.